CASI Pharmaceuticals, Inc (DE)
CASI Pharmaceuticals, Inc (DE) (CASI): 8 pipeline candidates · ~202 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
202.1 months
D/E 0.66 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for CASI Pharmaceuticals, Inc (DE)across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8M
Cash
$47.1M
Quarterly Burn
$843K
Runway
202.1 mo
Revenue
$15.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
Frequently asked questions
How many drug candidates are in CASI Pharmaceuticals, Inc (DE)'s pipeline?
CASI Pharmaceuticals, Inc (DE) (CASI) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CASI Pharmaceuticals, Inc (DE)'s lead drug candidate?
CASI Pharmaceuticals, Inc (DE)'s most advanced tracked candidate is aube00 (Phase 1) for Solid Tumors.
What is CASI Pharmaceuticals, Inc (DE)'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CASI Pharmaceuticals, Inc (DE) has approximately 202.1 months of cash runway.
What is CASI Pharmaceuticals, Inc (DE)'s market capitalization?
CASI Pharmaceuticals, Inc (DE)'s market capitalization is approximately $1.8M.
Who is the CEO of CASI Pharmaceuticals, Inc (DE)?
Crown Bioscience is the chief executive officer of CASI Pharmaceuticals, Inc (DE) (CASI).
Get the full picture on CASI Pharmaceuticals, Inc (DE)
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.